CCM
JSPRW icon

Context Capital Management’s Japer Therapeutics Warrants JSPRW Stock Holding History

Context Capital Management’s Portfolio JSPRW Stock Details JSPRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-25,000
Closed -$37K – 559
2021
Q3 		$37K Hold
25,000
– – ﹤0.01% 425
2021
Q2 		$29K Hold
25,000
– – ﹤0.01% 493
2021
Q1 		$21K Hold
25,000
– – ﹤0.01% 448
2020
Q4 		$36K Hold
25,000
– – ﹤0.01% 251
2020
Q3 		$30K Buy
+25,000
New +$25.3K 0.01% 154

Other funds holding JSPRW

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
ICMH
Integrity Capital Management (HK) Central, Hong Kong $64K AUM
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Context Capital Management's JSPRW Position: Q4 2021 in Review

Context Capital Management sold out of Japer Therapeutics Warrants (JSPRW) in Q4 2021, closing a stake of 25,000 shares — an estimated $37K sold.

Context Capital Management first reported a position in JSPRW in Q3 2020 and held it in 5 quarters. The position peaked at $37K in Q3 2021. 15 funds tracked by Wall St. Rank hold JSPRW as of Q4 2021.

  • Context Capital Management reported no remaining Japer Therapeutics Warrants position as of Q4 2021 after selling out during the quarter.
  • Context Capital Management sold 25,000 Japer Therapeutics Warrants shares in Q4 2021, an estimated $37K.
  • Context Capital Management first reported a position in Japer Therapeutics Warrants in Q3 2020 and held it in 5 quarters.
  • Context Capital Management's Japer Therapeutics Warrants position peaked at $37K in Q3 2021.
  • 15 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q4 2021.

Based on Context Capital Management's 13F filing for Q4 2021, filed 9 Feb 2022.